Cerebrospinal fluid biomarkers of central catecholamine deficiency in Parkinson's disease and other synucleinopathies.
about
Catecholamine autotoxicity. Implications for pharmacology and therapeutics of Parkinson disease and related disordersEfficacy of atomoxetine versus midodrine for the treatment of orthostatic hypotension in autonomic failure.Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease.Cerebrospinal fluid biomarkers in parkinsonian conditions: an update and future directionsDysautonomia in Parkinson diseaseDecreased vesicular storage and aldehyde dehydrogenase activity in multiple system atrophy.Deficient vesicular storage: A common theme in catecholaminergic neurodegeneration.Comparison of Monoamine Oxidase Inhibitors in Decreasing Production of the Autotoxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde in PC12 Cells.Concepts of scientific integrative medicine applied to the physiology and pathophysiology of catecholamine systems.Nilotinib Effects in Parkinson's disease and Dementia with Lewy bodies.Phenotype of postural instability/gait difficulty in Parkinson disease: relevance to cognitive impairment and mechanism relating pathological proteins and neurotransmitters.Norepinephrine deficiency in Parkinson's disease: the case for noradrenergic enhancement.Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases.Does response inhibition have pre- and postdiagnostic utility in Parkinson's disease?An update on the cerebellar subtype of multiple system atrophy.Cerebrospinal fluid biomarkers for Parkinson's disease - a systematic review.Insights into the human brain proteome: Disclosing the biological meaning of protein networks in cerebrospinal fluid.Early-Life Benzo[a]Pyrene Exposure Causes Neurodegenerative Syndromes in Adult Zebrafish (Danio rerio) and the Mechanism Involved.Cerebrospinal fluid levels of catecholamines and its metabolites in Parkinson's disease: effect of l-DOPA treatment and changes in levodopa-induced dyskinesia.Orthostatic hypotension is associated with decreased cerebrospinal fluid levels of chromogranin A in early stage of Parkinson disease.Elevated cerebrospinal fluid ratios of cysteinyl-dopamine/3,4-dihydroxyphenylacetic acid in parkinsonian synucleinopathies.Biomarker Research in Parkinson's Disease Using Metabolite Profiling.Cardiac sympathetic denervation without Lewy bodies in a case of multiple system atrophy.Potential clinical utility of multiple system atrophy biomarkers.An evidence base for noradrenergic deficits in Parkinson's disease.3-hydroxykynurenine and other Parkinson's disease biomarkers discovered by metabolomic analysis.Pure autonomic failure: Predictors of conversion to clinical CNS involvement.Evaluation of Serum Apolipoprotein E as a Potential Biomarker for Pharmacological Therapeutic Efficacy Monitoring in Dopamine Dictated Disease Spectrum of Schizophrenia and Parkinson's disease: A Preliminary Studyα-Synuclein and Noradrenergic Modulation of Immune Cells in Parkinson's Disease Pathogenesis
P2860
Q26826093-ED42F3B0-606D-4500-9D70-375791542441Q33164708-B45818F6-E78A-4B83-B0C6-80EAAB9788E0Q33896138-3415052E-F97B-4E8E-A11D-CE69E428F323Q34237637-B8E25420-C307-467E-A4B0-2A41BBE8DCF3Q34463831-1B83CECE-DC21-4F9B-A8E3-426C159EEE7AQ35638948-A1A5335A-1E5D-4345-BAE0-F2A19892A6DFQ36011221-AFA23BBA-AC3D-435A-A567-6A25DEA4C9A7Q36559682-69BE960C-DDF2-4A09-A6AA-34C4825A4BE9Q36992085-15ECE447-DB14-48C2-AE05-2718231BE4DDQ37225128-D917E49A-C3C5-4B81-A6FD-DA0ACCEE7427Q37717401-B4F177DF-1F1B-467E-B48A-9DE7D07DB306Q38258228-179BAAB7-6FEE-406C-BD9C-39BFAE54F5A9Q38289739-91836F19-26FC-4D9A-AFF9-7EF696D4A5A0Q38313013-52487635-7B88-4FCC-9617-2C6D27F41860Q38578814-79EF9492-2477-4E92-B465-C3B87D0E1E49Q38780220-5347C196-4A3F-4EE6-A26A-446DA50D21A7Q38844925-97E98A7F-BE53-492B-B745-2B38F3E47F30Q38885985-B33B3D54-2488-497C-B646-46669F2EAC60Q38937893-C6993C7B-3C71-43CC-81BB-65E1AE6B4D16Q41375590-773590E6-C824-44BC-AB5E-6AFE7CEBACA0Q41655727-15E7D73A-8E34-410B-964D-A30AC96502CFQ41666702-F8B8974D-AB2C-4C5B-BEBF-37D8BAEEC217Q42060109-A0BC6984-E678-4279-BD74-10EFCAD9CB2DQ47663712-BB315B0A-0423-4484-B3C5-10F2A49CC16EQ48351657-C801BD0D-53E6-48C7-8317-D33C52AED501Q50732857-EC168386-BFE1-4C14-A4BB-33C1A6A84B57Q54161356-C0B2C8AE-CAF2-4D78-8C13-45ED2B520896Q57480295-79CF0696-E90A-4EF4-A637-E8CB7190D065Q58750079-DE197BBF-A848-428D-94C2-FC0CEEB2846B
P2860
Cerebrospinal fluid biomarkers of central catecholamine deficiency in Parkinson's disease and other synucleinopathies.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Cerebrospinal fluid biomarkers ...... e and other synucleinopathies.
@ast
Cerebrospinal fluid biomarkers ...... e and other synucleinopathies.
@en
type
label
Cerebrospinal fluid biomarkers ...... e and other synucleinopathies.
@ast
Cerebrospinal fluid biomarkers ...... e and other synucleinopathies.
@en
prefLabel
Cerebrospinal fluid biomarkers ...... e and other synucleinopathies.
@ast
Cerebrospinal fluid biomarkers ...... e and other synucleinopathies.
@en
P2093
P2860
P921
P356
P1433
P1476
Cerebrospinal fluid biomarkers ...... e and other synucleinopathies.
@en
P2093
Courtney Holmes
David S Goldstein
Yehonatan Sharabi
P2860
P304
P356
10.1093/BRAIN/AWS055
P407
P577
2012-03-26T00:00:00Z